Quest Diagnostics (QDI) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

QDI Analyst Ratings

Moderate Buy

5 Buy

4 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Quest

Diagnostics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

QDI Stock 12 Month Forecast

Average Price Target

€230.64

▲(10.20% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is €230.64 with a high forecast of €236.39 and a low forecast of €223.01. The average price target represents a 10.20% change from the last price of €209.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"144":"€144","237":"€237","167.25":"€167.3","190.5":"€190.5","213.75":"€213.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":236.39059205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€236.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230.6418900211111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€230.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":223.0099925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€223.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[144,167.25,190.5,213.75,237],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,204.344,206.8091224653846,209.2742449307692,211.73936739615385,214.20448986153846,216.66961232692307,219.13473479230768,221.59985725769232,224.06497972307693,226.53010218846154,228.99522465384615,231.4603471192308,233.9254695846154,{"y":236.39059205,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,204.344,206.36691461700855,208.3898292340171,210.41274385102562,212.43565846803418,214.45857308504273,216.48148770205128,218.5044023190598,220.52731693606836,222.5502315530769,224.57314617008547,226.596060787094,228.61897540410254,{"y":230.6418900211111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,204.344,205.77984557692307,207.21569115384614,208.65153673076924,210.0873823076923,211.52322788461538,212.95907346153845,214.39491903846155,215.83076461538462,217.2666101923077,218.70245576923077,220.13830134615387,221.57414692307694,{"y":223.0099925,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":157.962,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.973,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.544,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.876,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.161,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.191,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.608,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.824,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.213,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.471,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.052,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.34,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.344,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€236.39

Average Price Target€230.64

Lowest Price Target€223.01

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luke Sergott

Barclays

€231.93

Buy

10.81%

Upside

Reiterated

10/23/26

Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), AxoGen (NASDAQ: AXGN) and Quest Diagnostics (NYSE: DGX)

Eric Coldwell

Robert W. Baird

€231.93→€233.71

Hold

11.66%

Upside

Reiterated

10/23/26

Quest Diagnostics price target raised to $262 from $260 at BairdQuest Diagnostics price target raised to $262 from $260 at Baird

Michael Ryskin

Bank of America Securities

€236.39

Buy

12.94%

Upside

Reiterated

10/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (NYSE: MOH), Quest Diagnostics (NYSE: DGX) and Argenx Se (NASDAQ: ARGX)

Kevin Caliendo

UBS

€218.55→€223.01

Hold

6.55%

Upside

Assigned

10/19/26

Quest Diagnostics price target raised to $250 from $245 at UBSQuest Diagnostics price target raised to $250 from $245 at UBS

David S Macdonald

Truist Financial

€223.01→€231.93

Hold

10.81%

Upside

Reiterated

09/22/26

Quest Diagnostics price target raised to $260 from $250 at TruistQuest Diagnostics price target raised to $260 from $250 at Truist

Erin Wright

Morgan Stanley

€231.93

Buy

10.81%

Upside

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX) and Irhythm Technologies (NASDAQ: IRTC)

Ann Hynes

Mizuho Securities

€231.93

Buy

10.81%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Quest Diagnostics (NYSE: DGX) and Otsuka Holdings Co (Other OTC: OTSKF)

David Toung

Argus Research

€231.93

Buy

10.81%

Upside

Reiterated

07/28/26

Argus Research Keeps Their Buy Rating on Quest Diagnostics (DGX)

Lisa Gill

J.P. Morgan

€196.25→€223.01

Hold

6.55%

Upside

Assigned

07/28/26

Quest Diagnostics price target raised to $250 from $220 at JPMorganQuest Diagnostics price target raised to $250 from $220 at JPMorgan

Tycho Peterson

Jefferies

€200.71→€218.55

Buy

4.42%

Upside

Reiterated

07/23/26

Quest Diagnostics price target raised to $245 from $225 at JefferiesQuest Diagnostics price target raised to $245 from $225 at Jefferies

Jared Haase

William Blair

―

Buy

―

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX) and MindWalk Holdings (NASDAQ: HYFT)

Elizabeth Anderson CFA

Evercore ISI

€187.33

Hold

-10.50%

Downside

Reiterated

04/20/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Centessa Pharmaceuticals (NASDAQ: CNTA) and Perspective Therapeutics (NYSE MKT: CATX)

Patrick B Donnelly

Citi

€169.49→€191.79

Hold

-8.37%

Downside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Biogen (NASDAQ: BIIB) and Quest Diagnostics (NYSE: DGX)

David Westenberg

Piper Sandler

€169.49→€178.41

Hold

-14.76%

Downside

Reiterated

10/27/25

Quest Diagnostics price target raised to $200 from $190 at Piper SandlerQuest Diagnostics price target raised to $200 from $190 at Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luke Sergott

Barclays

€231.93

Buy

10.81%

Upside

Reiterated

10/23/26

Analysts Offer Insights on Healthcare Companies: Helus Pharma (NASDAQ: HELP), AxoGen (NASDAQ: AXGN) and Quest Diagnostics (NYSE: DGX)

Eric Coldwell

Robert W. Baird

€231.93→€233.71

Hold

11.66%

Upside

Reiterated

10/23/26

Quest Diagnostics price target raised to $262 from $260 at BairdQuest Diagnostics price target raised to $262 from $260 at Baird

Michael Ryskin

Bank of America Securities

€236.39

Buy

12.94%

Upside

Reiterated

10/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (NYSE: MOH), Quest Diagnostics (NYSE: DGX) and Argenx Se (NASDAQ: ARGX)

Kevin Caliendo

UBS

€218.55→€223.01

Hold

6.55%

Upside

Assigned

10/19/26

Quest Diagnostics price target raised to $250 from $245 at UBSQuest Diagnostics price target raised to $250 from $245 at UBS

David S Macdonald

Truist Financial

€223.01→€231.93

Hold

10.81%

Upside

Reiterated

09/22/26

Quest Diagnostics price target raised to $260 from $250 at TruistQuest Diagnostics price target raised to $260 from $250 at Truist

Erin Wright

Morgan Stanley

€231.93

Buy

10.81%

Upside

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX) and Irhythm Technologies (NASDAQ: IRTC)

Ann Hynes

Mizuho Securities

€231.93

Buy

10.81%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Quest Diagnostics (NYSE: DGX) and Otsuka Holdings Co (Other OTC: OTSKF)

David Toung

Argus Research

€231.93

Buy

10.81%

Upside

Reiterated

07/28/26

Argus Research Keeps Their Buy Rating on Quest Diagnostics (DGX)

Lisa Gill

J.P. Morgan

€196.25→€223.01

Hold

6.55%

Upside

Assigned

07/28/26

Quest Diagnostics price target raised to $250 from $220 at JPMorganQuest Diagnostics price target raised to $250 from $220 at JPMorgan

Tycho Peterson

Jefferies

€200.71→€218.55

Buy

4.42%

Upside

Reiterated

07/23/26

Quest Diagnostics price target raised to $245 from $225 at JefferiesQuest Diagnostics price target raised to $245 from $225 at Jefferies

Jared Haase

William Blair

―

Buy

―

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX) and MindWalk Holdings (NASDAQ: HYFT)

Elizabeth Anderson CFA

Evercore ISI

€187.33

Hold

-10.50%

Downside

Reiterated

04/20/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Centessa Pharmaceuticals (NASDAQ: CNTA) and Perspective Therapeutics (NYSE MKT: CATX)

Patrick B Donnelly

Citi

€169.49→€191.79

Hold

-8.37%

Downside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Biogen (NASDAQ: BIIB) and Quest Diagnostics (NYSE: DGX)

David Westenberg

Piper Sandler

€169.49→€178.41

Hold

-14.76%

Downside

Reiterated

10/27/25

Quest Diagnostics price target raised to $200 from $190 at Piper SandlerQuest Diagnostics price target raised to $200 from $190 at Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Quest Diagnostics

3 Months

Michael RyskinBank of America Securities

Success Rate

11/12 ratings generated profit

Average Return

+6.12%

Copying Michael Ryskin's trades and holding each position for 3 Months would result in 91.67% of your transactions generating a profit, with an average return of +6.12% per trade.

1 Year

Michael RyskinBank of America Securities

Success Rate

12/12 ratings generated profit

Average Return

+22.02%

Copying Michael Ryskin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.02% per trade.

2 Years

Michael RyskinBank of America Securities

Success Rate

12/12 ratings generated profit

Average Return

+44.45%

Copying Michael Ryskin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +44.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

QDI Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, QDI has received 5 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. QDI average Analyst price target in the past 3 months is 230.64.

Each month's total comprises the sum of three months' worth of ratings.

QDI Financial Forecast

QDI Earnings Forecast

Next quarter’s earnings estimate for QDI is €2.39 with a range of €2.35 to €2.44. The previous quarter’s EPS was €2.68. QDI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year QDI has Performed in-line its overall industry.

QDI Sales Forecast

Next quarter’s sales forecast for QDI is €2.70B with a range of €2.66B to €2.73B. The previous quarter’s sales results were €2.76B. QDI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year QDI has Performed in-line its overall industry.

QDI Stock Forecast FAQ

What is DE:QDI’s average 12-month price target, according to analysts?

Based on analyst ratings, Quest Diagnostics’s 12-month average price target is 230.64.

What is DE:QDI’s upside potential, based on the analysts’ average price target?

Quest Diagnostics has 10.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Quest Diagnostics a Buy, Sell or Hold?

Quest Diagnostics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.

What is Quest Diagnostics’s share price target?

The average share price target for Quest Diagnostics is 230.64. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €236.39 ,and the lowest forecast is €223.01. The average share price target represents 10.20% Increase from the current price of €209.3.

What do analysts say about Quest Diagnostics?

Quest Diagnostics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Quest Diagnostics?

To buy shares of DE:QDI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Quest Diagnostics (QDI) Stock Forecast & Price Target

QDI Analyst Ratings

QDI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Quest Diagnostics

QDI Analyst Recommendation Trends

QDI Financial Forecast

QDI Earnings Forecast

QDI Sales Forecast

QDI Stock Forecast FAQ

Detailed List of Analyst Forecasts